Incorporated in March
2003, Mukka Proteins manufactures fish protein products. The company produces
and supplies fish meal, fish oil and fish soluble paste, which are essential
ingredients for production of aqua feed (for fish and shrimp), poultry feed
(for broilers and layers) and pet food (for dog and cat food).
The company is one of
the key players in the fish protein industry in India. In Fiscal 2023, the total
estimated revenue of the Indian fish meal and fish oil industry was between Rs
3200 crore to Rs 4100 crore, while the revenue of Mukka Proteins was Rs 1066.39
crore, thus contributing 25%-30% to the estimated revenue of the Indian fish
meal and fish oil industry.
The company sells its products
domestically and exports to over 10 countries, including Bahrain, Bangladesh,
Chile, Indonesia, Malaysia, Myanmar, Philippines, China, Saudi Arabia, South
Korea, Oman, Taiwan, and Vietnam. In H1 FY2024, the domestic market represented
32.25% of sales and exports 67.75%.
The company’s key raw
material is pelagic fish (raw fish), which is sourced from the local fish
catchers. Pelagic fish and fish remains are used to manufacture fish meal, fish
oil and fish soluble paste. The company also imports fish meal from overseas
suppliers, including its foreign subsidiary, Ocean Aquatic Proteins.
Import of raw materials
by the company accounted for 1.13% and 0.83%, 3.74%, and 20.79% of the revenue
from operations for the six months period ended September 30, 2023, and for
Fiscal 2023, Fiscal 2022 and Fiscal 2021, respectively.
As of September 30,
2023, fish meal contributed 86.16% to total sales, fish oil 8.85%, fish soluble
paste 2.25%, and others 2.74%. Its product fish oil finds application in soap
manufacturing, leather tanneries, paint industries and pharmaceutical products.
Additionally, Omega-3 pills and related products derived from fish oil are
gaining importance as high nutrient and healthy dietary supplements.
The company operates
six manufacturing facilities, of which four are in India and two are held
through foreign subsidiary Ocean Aquatic Proteins located in Oman. Further, the
company operates three blending facilities and five storage facilities in
India. As on September 30, 2023, its annualized aggregate manufacturing
capacity was 115050 tpa of fish meal, 16950 tpa of fish oil, and 20340 tpa of
fish soluble paste.
Mukka manufacturing facility
I holds international certifications such as GMP+, Halal, HACCP, EIA, MPEDA and
it is a member of IFFO. Further, the Oman Manufacturing Facility I is ISO
9001:2015, ISO 22000:2018 certified by Times NQA, UKAS Management Systems and
GMP+.
The company is
evaluating opportunities for setting-up new state-of-the art manufacturing
facilities in the eastern coastal states of India as a strategy to have
seamless access to raw materials i.e. pelagic fish and diversify the over
dependency on the western costal fishing catchments.
The company also manufactures
and sells insect meal and insect oil (insect protein) through EPPL, its associate.
In terms of revenue contribution from partnership firms, Ullal Fish Meal and
Oil contributed 8.73% to sales in H1 FY2024, Mangalore Fish Meal and Oil 4.02%,
Pacific Marine Products 1.19%, and Progress Frozen and Fish Sterilizetion
6.55%.
The company sources
fish meal, fish oil and fish soluble paste as raw materials from partnership
firms Ullal Fish Meal and Oil Company, Mangalore Fish Meal and Oil Company,
Progress Frozen and Fish Sterilizetion, and Pacific Marine Products. The company
has made substantial capital infusion in them and in third-party manufacturing
units.
Mukka Proteins is among
the first few companies to have introduced the steam-dried process in India for
manufacturing of fish meal.
The company aims to
deepen its presence in existing export markets such as China, Chile, and Japan.
Additionally, the company plans to enter new markets such as USA and Turkey.
Offer and its objects
The IPO is entirely a fresh
issue of 8,00,00,000 equity shares aggregating up to Rs 224 crore.
The price band for the
IPO is Rs 26 to Rs 28 per equity share of face value Re 1 each.
The objectives for the
fresh issue includes Rs 120 crore for funding working capital requirement, Rs
10 crore for investment in associate, and remaining amount for general
corporate purpose.
The promoters of the company
are Kalandan Mohammed Haris, Kalandan Mohammad Arif, and Kalandan Mohammed
Althaf. The promoters and promoter group hold an aggregate of 22,00,00,000 equity
shares aggregating to 100% of the pre-offer issued and paid-up equity share
capital. Their post IPO shareholding is expected to be around 73.33%.
The issue, through the book-building process,
will open on 29 February 2024 and close on 4 March 2024.
Strengths
The company’s revenue registered CAGR of 39.62%
from Rs 603.83 crore in Fiscal 2021 to Rs 1177.12 crore in Fiscal 2023.
Further, the company had a market share of 25% - 30% of the fish meal and fish
oil industry in India for Fiscal 2023.
All its facilities are strategically located
within proximity to the coastline, enabling easy access to fresh, adequate, and
cost-effective key raw material. Additionally, it helps optimize transport costs.
The company operates in an industry with a large
addressable market. Moreover, to capture a larger wallet share, the company is
strengthening its foothold in existing markets and is expanding to new
geographies.
The company has been consistently awarded by
MPEDA, during the last seven years, for its export performance, inter alia,
including outstanding performance in export of fish meal, fish oil and allied
products for Fiscal 2021, Fiscal 2020 and Fiscal 2019.
The company has good relationships with its
customers and receives most of the business from long-term customers. For
instance, the company has a relationship of more than five years with 19.61% of
total customers, contributing 52.90 % to its revenue.
The company maintains a high standard of quality
along with complying with stringent specifications for its products. It has received
quality certifications such as GMP+, ISO 9001:2015, ISO 22000:2018 certified by
NQA, UKAS Management Systems. It holds license from AQSIQ (Administration of
Quality Supervision, Inspection and Quarantine), China.
In view of growing industry demand, the company
is expanding its presence in a new protein source (insect-based nutrition). The
company holds 50% of the total paid-up equity share capital of EPPL, manufacturing
insect proteins.
Weaknesses
The company’s operations are weather-sensitive
and face risks from cyclonic storms, unpredictable rainfall, and potential El
Niño effects, affecting raw material procurement and processing.
The company derives most of its revenue from a limited
number of customers. In the six months period ended September 30, 2023, and in
Fiscal 2023, Fiscal 2022 and Fiscal 2021, its top 2 customers contributed 42.17
% and 36.91%, 62.25% and 69.06%, respectively.
The company and some of its subsidiaries, promoters,
directors, and group companies are party to legal proceedings (including
criminal proceedings). Any adverse outcome of the proceedings could have an
impact on the company’s operations.
The company is exposed to risks arising from
exchange rate fluctuations as a substantial portion of the revenue is generated
from exports. In Fiscal 2021, Fiscal 2022, Fiscal 2023 and in the six months
period ended September 30, 2023, exports contributed 52.72%, 20.05% and 52.61%
and 62.68% to revenue, respectively.
The company recorded negative cash flows from
operating activities in the six months period ending September 30, 2023, and FY2023.
If the company continues to post negative operating cash flows, its business
could be materially affected.
The company is unable to properly utilize its
capacity. For the Fiscals 2023, 2022 and 2021, the overall capacity utilization
of manufacturing facilities in India was 24.02%, 29.31%, 20.71% and 17.36%,
respectively, and that of its manufacturing facility in Oman was 16.06%,
15.96%, 26.73% and 36.73%, respectively.
The company majorly supply its products to aqua
feed, poultry feed and pet food industry. Outbreaks of any livestock diseases
in general, and shrimp and poultry disease in particular, can significantly
restrict the company’s ability to conduct operations.
There have been instances of non-compliance with
certain regulatory filings. Moreover, there have been instances of delays in
filing certain GST returns and making payments under the Employees Provident
Fund. Consequently, the company may be subject to regulatory actions and
penalties.
Valuation
Consolidated sales
were up by 52.77% to Rs 1177.12 crore in FY 2023 as compared to FY2022. The OPM
increased by 114 bps to 7.32%, which led to an 81.09% increase in OP to Rs
86.17 crore. OI increased 18.41% to Rs 6.68 crore, while interest cost
increased 70.22% to Rs 16.48 crore and depreciation jumped 38.62% to Rs 11.89
crore. PBT increased 83.28% to Rs 65.95 crore. Tax expenses were Rs 18.42 crore
as compared to Rs 10.16 crore in FY22. Minority interest increased 114.15% to
Rs 3.45 crore. Net profit rose 82.07% to Rs 44.08 crore.
The FY2023 EPS on post-issue equity works out to
Rs 1.47. At the upper price band of Rs 28, the P/E works out to 19.
There is no listed company in India strictly
comparable with Mukka Proteins. Hence, aqua feed companies are considered for comparison,
as these companies are the largest customers of fish meal.
As of 27 February
2024, listed peers such as Avanti Feeds traded at TTM P/E of 20, Godrej Agrovet
at TTM P/E of 30, and Zeal Aqua at TTM P/E of 21. For FY2023, Mukka Protiens’
OPM and RoE stood at 7.32% and 36.71%, respectively, as compared to 7.73% and
13.29% for Avanti Feeds, 5.58% and 12.91% for Godrej Agrovet and 5.23% and 9.96%
for Zeal Aqua, respectively.
Mukka
Proteins: Issue highlights
|
For Fresh Issue Offer size (in Rs crore)
|
|
- On lower price band
|
208
|
- On upper price band
|
224
|
Offer size (in no of shares )
|
8,00,00,000
|
Price band (Rs)
|
26-28
|
Minimum Bid Lot (in no. of shares )
|
535
|
Post issue capital (Rs crore)
|
|
- On lower price band
|
30
|
- On upper price band
|
30
|
Post-issue promoter & Group shareholding (%)
|
73.33
|
Issue open date
|
29-02-2024
|
Issue closed date
|
04-03-2024
|
Listing
|
BSE, NSE
|
Rating
|
43/100
|
Mukka Proteins: Restated
Consolidated Financials
|
|
2103 (12)
|
2203 (12)
|
2303 (12)
|
2309 (6)
|
Sales
|
603.83
|
770.50
|
1,177.12
|
606.09
|
OPM (%)
|
3.62%
|
6.18%
|
7.32%
|
9.01%
|
OP
|
21.88
|
47.59
|
86.17
|
54.60
|
Other inc.
|
6.12
|
5.64
|
6.68
|
6.79
|
PBIDT
|
28.00
|
53.23
|
92.85
|
61.39
|
Interest
|
8.02
|
9.68
|
16.48
|
12.33
|
PBDT
|
19.98
|
43.55
|
76.38
|
49.07
|
Dep.
|
8.34
|
8.58
|
11.89
|
6.08
|
PBT
|
11.64
|
34.97
|
64.49
|
42.99
|
Share of Profit/(Loss) from Associates/JV
|
3.82
|
1.01
|
1.46
|
(0.09)
|
PBT before EO
|
15.46
|
35.98
|
65.95
|
42.90
|
Exceptional items
|
-
|
-
|
-
|
-
|
PBT after EO
|
15.46
|
35.98
|
65.95
|
42.90
|
Taxation
|
4.45
|
10.16
|
18.42
|
9.92
|
PAT
|
11.01
|
25.82
|
47.53
|
32.98
|
Minority Interest
|
2.03
|
1.61
|
3.45
|
0.65
|
Net Profit
|
8.98
|
24.21
|
44.08
|
32.33
|
EPS (Rs)*
|
0.30
|
0.81
|
1.47
|
#
|
* EPS is annualized on post issue equity capital of Rs 30 crore of
face value of Re 1 each
|
|
|
# EPS is not annualised due to seasonality of business
|
|
|
|
EO: Extraordinary items. EPS is calculated after excluding EO and
relevant tax
|
|
|
Figures in Rs crore
|
|
|
|
|
Source: Capitaline Corporate Database
|
|
|
|
|
|